摘要
用免疫组化法检测了５５例乳腺癌和１３例乳腺良性病变的增殖细胞核抗原（ＰＣＮＡ）。结果ＰＣＮＡ增殖指数在乳腺用为０％～８１％（中位数２０％），在乳腺良性病变为０％～６８％（中位数５％），乳腺癌中高于乳腺良性病变（Ｐ＜０．００２）．在乳腺癌中ＰＣＮＡ表达与组织学分级（Ｐ＜０．００１）、淋巴结转移（Ｐ＜０．０１）及组织蛋白酶Ｄ（ＣａｔｈＤ）间质表达（Ｐ＜０．０２５）呈正相关，与ＣａｔｈＤ实质表达（Ｐ＜０．０２５）、无病生存期（Ｐ＜０．０２５）及总生存期（Ｐ＜０．０５）呈负相关。提示ＰＣＮＡ能反映细胞的增殖状态，其高表达可预测复发率高和生存期短，检测ＰＣＮＡ对乳腺癌的辅助治疗可能有帮助。
Using anti-PCNA monoclonal antibody(PC10),an immuno-histochemical assay was performed on tissue sections from 55 cases of breast cancer and 13 cases of breast benign diseases.The proliferating cell nuclear antigen(PCNA) labeling index varied from 0%￣81% (Median:20%) in breast cancers and 0%￣68% (Median:5%) in breast benign diseases(P<0.002).The PCNA expression was positively correlated with histologic grade(P<0.01),lymph node involvement (P<0.01) and cathepsin D expression in stromal cells,but negatively correlated with cathepsin D expression in cancer cells, disease-free survival and overall survival.These results suggest that high PCNA expression could predict the potentiality of relapse,and the determination of PCNA might be an useful indicator for adjuvant therapy in breast cancer.
出处
《实用肿瘤杂志》
CAS
北大核心
1996年第5期202-204,共3页
Journal of Practical Oncology
关键词
增殖细胞核抗原
乳腺癌
预后
proliferating cell nuclear antigen
breast cancer
prognosis
